Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Teladoc

Don't overlook these major healthcare names on your next stock-buying spree.

Got $1,000? 2 Smart Stocks to Consider Buying Right Now

Amazon

Got $1,000? 2 No-Brainer Stocks to Buy and Hold for at Least the Next Decade

AbbVie

CRISPR Therapeutics

Catalysts lie ahead for these promising stocks.

3 Top Healthcare Stocks to Buy for November

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts on the company's portfolio of cystic fibrosis (CF) medicines will be presented in posters and oral presentations at this year's North American Cystic Fibrosis Conference (NACFC), including studies demonstrating the clinical benefits and long-term safety of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor).

Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference

Campbell Soup

McKesson

Bear Market Investing: Should You Buy Today's Top Performers?

Baidu

PayPal

The innovation-packed Nasdaq 100 has three screaming bargains that are ripe for the picking.

3 Nasdaq 100 Stocks to Buy Hand Over Fist in November

The big biotech has a cash stockpile of nearly $10 billion. Here's how Vertex plans to use the money.

Is Vertex Pharmaceuticals About to Become a Dividend Stock?

There are five great reasons this stock should continue to soar.

Here's a No-Brainer Stock to Buy Now That's Trouncing the Market

Alphabet

It could be time to party like it's 2009.

This Bear Market Could Be the Best Investing Opportunity in More Than a Decade

A strong earnings report after the close on Thursday pushed the stock higher all day Friday.

Why Shares of Vertex Pharmaceuticals Jumped 9.03% on Friday

Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022.

Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q3 2022 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Dr. Reshma Kewalramani - President and CEO Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Salveen Richter - Goldman Sachs Phil Nadeau - Cowen & Company Evan Seigerman - BMO David Risinger - SVB Securities Kripa Devarakonda - Truist Securities Jessica Fye - JPMorgan Operator Good day. And welcome to the Vertex Pharmaceuticals Third Quarter 2022 Earnings Call.

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2022 Earnings Call Transcript

Vertex (VRTX) delivered earnings and revenue surprises of 8.67% and 4.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates

Vertex Pharma beat third-quarter expectations Thursday and raised its sales outlook, helping VRTX stock shrug off some regular session pain. The post Vertex Pharmaceuticals Jumps After Quarterly Beat, Raises 2022 Outlook appeared first on Investor's Business Daily.

Vertex Pharmaceuticals Jumps After Quarterly Beat, Raises 2022 Outlook

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2022 and increased its full year 2022 revenue guidance.

Vertex Reports Third Quarter 2022 Financial Results

Dollar General

Johnson & Johnson

Moderna

Walmart

Recession-proof stocks must offer something that makes investors want to buy them even when the economy is tanking.

Which Stocks Are Most Likely to Thrive in a Recession? Here's What History Shows

Match Group

2 Powerhouse Stocks That Could Go Parabolic

Cardinal Health

Genuine Parts

Cheniere Energy

Steel Dynamics

S&P 500 giant Vertex and Cheniere Energy, the largest U.S. liquefied natural gas producer, are setting up bullishly in the bear market. The post S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength appeared first on Investor's Business Daily.

S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength

Corcept Therapeutics

Catalyst Pharmaceuticals

Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.

These 3 Stocks Are Winning the Bear Market -- Here's How

Alnylam Pharmaceuticals

Amgen

BioCryst Pharmaceuticals

Beam Therapeutics

Graphite Bio

Ionis Pharma

Intellia Therapeutics

Pfizer

Regeneron Pharmaceuticals

Takeda Pharmaceutical

Verve Therapeutics

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

T-Mobile US

Is it too late to buy these stocks or are their shares likely to continue rising?

2 Unstoppable Stocks That Are Beating the Bear Market

Disney

My Best Stocks to Buy Now and Hold Forever

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the financial markets close.

Vertex to Announce Third Quarter 2022 Financial Results on October 27

AMN Healthcare Services

Intuitive Surgical

Here we discuss two Medical companies, VRTX, ISRG and AMN, that may prove to be wealth creators for investors over the long term on the back of their strong fundamentals.

3 Medical Stocks to Buy in 2022 for Long-Term Resilience

The FDA clears Vertex's (VRTX) Investigational New Drug application for VX-634, a small molecule AAT corrector, thereby allowing the company to initiate a first-in-human clinical study in healthy volunteers.

Vertex Pharmaceuticals' (VRTX) New AAT Corrector Enters Clinic

News for Vertex Pharmaceuticals Stock (VRTX)